用于治疗胱氨酸病患者角膜胱氨酸晶体沉积的盐酸半胱胺滴眼液：一项循证综述
Cysteamine hydrochloride eye drop solution for the treatment of corneal cystine crystal deposits in patients with cystinosis: an evidence-based review.
作者信息
Makuloluwa Achini K, Shams Fatemeh
机构信息
Tennent Institute of Ophthalmology, Gartnavel General Hospital, Glasgow, UK.
出版信息
Clin Ophthalmol. 2018 Jan 24;12:227-236. doi: 10.2147/OPTH.S133516. eCollection 2018.
Abstract
Cystinosis is a rare, autosomal recessive disorder leading to defective transport of cystine out of lysosomes. Subsequent cystine crystal accumulation can occur in various tissues, including the ocular surface. This review explores the efficacy of cysteamine hydrochloride eye drops in the treatment of corneal cystine crystal accumulation and its safety profile.
摘要
胱氨酸病是一种罕见的常染色体隐性疾病，可导致胱氨酸从溶酶体中转运缺陷。随后，胱氨酸晶体可在包括眼表在内的各种组织中蓄积。本综述探讨了盐酸半胱胺滴眼液治疗角膜胱氨酸晶体蓄积的疗效及其安全性。
相似文献
1
Cysteamine hydrochloride eye drop solution for the treatment of corneal cystine crystal deposits in patients with cystinosis: an evidence-based review.用于治疗胱氨酸病患者角膜胱氨酸晶体沉积的盐酸半胱胺滴眼液：一项循证综述
Clin Ophthalmol. 2018 Jan 24;12:227-236. doi: 10.2147/OPTH.S133516. eCollection 2018.
2
A new gel formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis: the Cystadrops OCT-1 study.一种用于治疗胱氨酸病中角膜胱氨酸结晶的新型局部用半胱胺凝胶制剂：Cystadrops OCT-1研究。
Mol Genet Metab. 2014 Mar;111(3):314-320. doi: 10.1016/j.ymgme.2013.12.298. Epub 2014 Jan 9.
3
Long-term follow-up of cystinosis patients treated with 0.55% cysteamine hydrochloride.胱氨酸病患者接受 0.55%盐酸半胱氨酸治疗的长期随访。
Br J Ophthalmol. 2021 May;105(5):608-613. doi: 10.1136/bjophthalmol-2020-316450. Epub 2020 Jun 27.
4
Efficacy and Safety of Topical Cysteamine in Corneal Cystinosis: A Systematic Review and Meta-Analysis.局部半胱氨酸治疗角膜胱氨酸沉积症的疗效和安全性：系统评价和荟萃分析。
Am J Ophthalmol. 2021 Mar;223:275-285. doi: 10.1016/j.ajo.2020.07.052. Epub 2020 Sep 2.
5
[Ocular treatment of cystinosis with eye drop containing cysteamine].[用含半胱胺的滴眼液对胱氨酸病进行眼部治疗]
Orv Hetil. 2022 May 22;163(21):846-852. doi: 10.1556/650.2022.32484.
6
A New Viscous Cysteamine Eye Drops Treatment for Ophthalmic Cystinosis: An Open-Label Randomized Comparative Phase III Pivotal Study.一种用于治疗眼型胱氨酸病的新型粘性半胱胺滴眼液：一项开放标签随机对照III期关键研究。
Invest Ophthalmol Vis Sci. 2017 Apr 1;58(4):2275-2283. doi: 10.1167/iovs.16-21080.
7
Effects of long-term cysteamine treatment in patients with cystinosis.胱氨酸病患者长期半胱胺治疗的效果。
Pediatr Nephrol. 2019 Apr;34(4):571-578. doi: 10.1007/s00467-017-3856-4. Epub 2017 Dec 19.
9
Ophthalmic Outcome in a Belgian Cohort of Cystinosis Patients Treated with a Compounded Preparation of Cysteamine Eye Drops: Retrospective Analysis.比利时胱氨酸病患者使用复方半胱胺滴眼液治疗的眼科结局：回顾性分析
Ophthalmol Ther. 2019 Dec;8(4):623-633. doi: 10.1007/s40123-019-00216-x. Epub 2019 Sep 27.
10
Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops.肾病性胱氨酸病中的角膜晶体：自然病史及半胱胺滴眼液治疗
Mol Genet Metab. 2000 Sep-Oct;71(1-2):100-20. doi: 10.1006/mgme.2000.3062.
引用本文的文献
1
The Use of a Viscous Cysteamine Eyedrop in a Belgian Cohort: Early 3-Year Results.在比利时队列中使用粘性半胱胺滴眼液：3年早期结果
Ophthalmol Ther. 2025 Aug;14(8):2043-2053. doi: 10.1007/s40123-025-01170-7. Epub 2025 Jun 8.
2
Pediatric cystinosis: Corneal cystine deposits and papilledema in a 4-year-old: A case report.小儿胱氨酸病：一名4岁患儿的角膜胱氨酸沉积和视乳头水肿：病例报告
Med Int (Lond). 2025 May 14;5(4):43. doi: 10.3892/mi.2025.242. eCollection 2025 Jul-Aug.
3
An Open-Label, Phase III Study to Assess the Efficacy and Safety of Cysteamine Ophthalmic Solution 0.55% in Japanese Cystinosis Patients.一项评估0.55%半胱胺滴眼液在日本胱氨酸病患者中的疗效和安全性的开放标签III期研究。
Clin Ophthalmol. 2024 Nov 25;18:3457-3471. doi: 10.2147/OPTH.S479770. eCollection 2024.
4
Ocular Involvement in Patients with Infantile Nephropathic Cystinosis.胱氨酸贮积症患儿的眼部受累。
Turk J Ophthalmol. 2024 Aug 28;54(4):235-239. doi: 10.4274/tjo.galenos.2024.89957.
5
Development and Evaluation of Different Electrospun Cysteamine-Loaded Nanofibrous Webs: A Promising Option for Treating a Rare Lysosomal Storage Disorder.不同载有半胱胺的电纺纳米纤维网的开发与评估：治疗一种罕见溶酶体贮积症的有前景选择
Pharmaceutics. 2024 Aug 9;16(8):1052. doi: 10.3390/pharmaceutics16081052.
6
Oxidative Stress and Antioxidant-Based Interventional Medicine in Ophthalmology.眼科中的氧化应激与基于抗氧化剂的介入医学
Pharmaceuticals (Basel). 2023 Aug 12;16(8):1146. doi: 10.3390/ph16081146.
7
The TGM2 inhibitor cysteamine hydrochloride does not impact corneal epithelial and stromal wound healing in vitro and in vivo.TGM2 抑制剂半胱胺盐酸盐在体内外均不影响角膜上皮和基质的伤口愈合。
Exp Eye Res. 2023 Jan;226:109338. doi: 10.1016/j.exer.2022.109338. Epub 2022 Dec 5.
8
Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems: Stability and Ocular Biopermanence.创新单剂量系统包装的透明质酸中胱胺滴眼液：稳定性和眼内生物持久性
Pharmaceutics. 2022 Oct 15;14(10):2194. doi: 10.3390/pharmaceutics14102194.
9
Development of a fibrin-mediated gene delivery system for the treatment of cystinosis via design of experiment.通过实验设计开发用于治疗胱氨酸病的纤维蛋白介导的基因递送系统。
Sci Rep. 2022 Mar 8;12(1):3752. doi: 10.1038/s41598-022-07750-y.
10
Analysis of tear film in cystinosis patients treated with topical viscous cysteamine hydrochloride (Cystadrops).分析经局部粘性盐酸半胱氨酸（Cystadrops）治疗的胱氨酸病患者的泪膜。
Eur J Ophthalmol. 2022 Nov;32(6):3358-3362. doi: 10.1177/11206721221078649. Epub 2022 Feb 7.
本文引用的文献
1
A New Viscous Cysteamine Eye Drops Treatment for Ophthalmic Cystinosis: An Open-Label Randomized Comparative Phase III Pivotal Study.一种用于治疗眼型胱氨酸病的新型粘性半胱胺滴眼液：一项开放标签随机对照III期关键研究。
Invest Ophthalmol Vis Sci. 2017 Apr 1;58(4):2275-2283. doi: 10.1167/iovs.16-21080.
2
Ocular Complications of Infantile Nephropathic Cystinosis.婴儿型肾性胱氨酸病的眼部并发症
J Pediatr. 2017 Apr;183S:S19-S21. doi: 10.1016/j.jpeds.2016.12.055.
3
Efficacy of topical cysteamine in nephropathic cystinosis.局部用半胱胺治疗肾病性胱氨酸病的疗效
Br J Ophthalmol. 2017 Sep;101(9):1234-1237. doi: 10.1136/bjophthalmol-2016-309278. Epub 2017 Jan 5.
4
Preformulation of cysteamine gels for treatment of the ophthalmic complications in cystinosis.用于治疗胱氨酸病眼部并发症的半胱胺凝胶的处方前研究。
Int J Pharm. 2016 Dec 30;515(1-2):575-582. doi: 10.1016/j.ijpharm.2016.10.044. Epub 2016 Oct 19.
5
Synergistic Cysteamine Delivery Nanowafer as an Efficacious Treatment Modality for Corneal Cystinosis.协同递送半胱胺的纳米晶片作为治疗角膜胱氨酸病的有效治疗方式
Mol Pharm. 2016 Oct 3;13(10):3468-3477. doi: 10.1021/acs.molpharmaceut.6b00488. Epub 2016 Sep 7.
6
Effect of pH and penetration enhancers on cysteamine stability and trans-corneal transport.pH值和渗透促进剂对半胱胺稳定性及经角膜转运的影响。
Eur J Pharm Biopharm. 2016 Oct;107:171-9. doi: 10.1016/j.ejpb.2016.07.009. Epub 2016 Jul 6.
7
Cystinosis: a review.胱氨酸病：综述
Orphanet J Rare Dis. 2016 Apr 22;11:47. doi: 10.1186/s13023-016-0426-y.
8
Lysosomal Storage Disorders in Egyptian Children.埃及儿童的溶酶体贮积症
Indian J Pediatr. 2016 Aug;83(8):805-13. doi: 10.1007/s12098-015-2014-x. Epub 2016 Feb 2.
9
Excellent long-term outcome of renal transplantation in cystinosis patients.胱氨酸病患者肾移植的长期效果良好。
Orphanet J Rare Dis. 2015 Jul 25;10:90. doi: 10.1186/s13023-015-0307-9.
10
Treatment of corneal cystine crystal accumulation in patients with cystinosis.胱氨酸病患者角膜胱氨酸晶体积聚的治疗
Clin Ophthalmol. 2014 Oct 10;8:2077-84. doi: 10.2147/OPTH.S36626. eCollection 2014.
Zotero 插件